When: Q3 2026 earnings print (late October)

Then: Reassess full position sizing based on results

TRIM - reduce position 30-50% and rotate into DHR and A; keep core long-term position; stop at $585

• Consensus target is $645 vs current price of $658, creating limited upside but meaningful downside dispersion
• Stock is 86% of way from Bollinger middle to upper band, extended 10.5% above 50 SMA ($595), sitting less than $9 from mechanical resistance at $666.79
• RSI at 69.6 is not overbought in isolation but signals risk/reward compression and marginal buyer paying up
• PEG of 1.96 with forward P/E of 23.9x implies ~48% EPS growth; Q2 2026 actual was only 9.3% EPS growth, creating multiple compression risk
• Gap fill zone at $615-$641 represents $17-$43 below current price, implying 3-7% drawdown risk if filled
• AI-pharma R&D thesis is 2027-2028 narrative based on CEO conference comments two weeks ago; narrative-driven at 52-week high
• Precure JV and Mayo Clinic partnership provide strategic optionality but no near-term revenue impact
• Macro environment with elevated 10-year yield creates structural ceiling on multiple expansion for premium-multiple names
• True asymmetry: downside to 50 SMA ($595) is ~10% or breakout base ($585) ~11% in disappointment scenario, not 5-8%
• Stop level at $585 reflects appropriate downside discipline; rotation to DHR and A reduces idiosyncratic single-name risk
• 96% probability of no rate cuts means higher-for-longer regime persists as headwind to re-rating
• $243B market cap with $54.8B goodwill at risk from $8.87B integration creates concentration risk at 52-week high into binary catalyst

→ vs aggressive: Survivor bias in bull case target dispersion; consensus at $645 is what institutional money actually prices against, not the $839 midpoint of three TIKR targets

→ vs aggressive: RSI 69.6 not a sell signal but also not a good entry point to ADD at full size; easy money already made when RSI is 60-75 in strong trends

→ vs aggressive: Gap fill risk of 3-7% from $615-$641 zone is meaningful; treating it as guaranteed support conflates 'often holds' with 'always holds'

→ vs aggressive: Premium PEG of 1.96 and P/E of 23.9x is fragile into binary Q3 print; any disappointment triggers de-rating on already-stretched multiple

→ vs aggressive: AI-pharma 2027-2028 CEO narrative is narrative-driven investing; stock already up 36% in six months so narrative partially digested

→ vs aggressive: Precure JV and Mayo Clinic strategic optionality don't generate revenue this quarter or next; conflating good long-term story with good trade right now

→ vs aggressive: Higher-for-longer regime is ceiling not floor for premium-multiple names; defensive doesn't mean multiple-immune

→ vs aggressive: Rotation to DHR and A is disciplined capital deployment, not portfolio mediocrity; reduces concentration risk without sacrificing sector view

→ vs aggressive: Actual asymmetry is 10-11% downside to $595-$585 vs meaningful-but-compressed upside in beat-and-raise scenario, not the 15-25% upside vs 5-8% downside framed

→ vs neutral: Err on side of capital preservation; cost of wrong trim is recoverable (recapture on pullback), cost of wrong hold is 10-15% drawdown into earnings with stretched multiple

15-25% trim (measured reduction from full position); stop at $585; re-enter on breakout confirmation above $666.79 with volume >2.5M OR on pullback to $625-$641 zone; rotate 50-60% of freed capital to DHR and A, holding remainder as dry powder

• Actual consensus target is $645 (not $839 bull midpoint); TMO trading at $658 above consensus with stretched PEG and binary catalyst 4 weeks out creates asymmetric risk to downside
• Technical setup shows 86% to upper Bollinger band, 10.5% above 50 SMA, and mechanical resistance at $666.79; easy money has been made
• $615-$641 zone is meaningful support but filling would mean 3-7% drawdown into binary catalyst
• PEG of 1.96 prices in growth not yet demonstrated; Q2 +9.3% EPS growth vs 48% growth implied by forward P/E
• 15-25% trim harvests gains at 52-week high, reduces concentration into binary catalyst, preserves core position for structural thesis
• Q3 earnings print should drive next major decision: beat-and-raise validates thesis, in-line/miss warrants maintained trim, disappointment triggers conservative worst case

→ vs aggressive: Using $839 bull midpoint as consensus is cherry-picking the optimistic scenario; actual consensus sits at $645 and TMO is already trading above it, creating asymmetric downside risk rather than asymmetric upside

→ vs aggressive: RSI of 69.6 combined with 86% to Bollinger band, 10.5% above 50 SMA, and <$9 from resistance at $666.79 creates a crowded technical setup where the easy money has been made

→ vs aggressive: Gap-and-go support at $615-$641 is not guaranteed; filling the gap creates 3-7% drawdown into binary catalyst, and technical report itself recommends adding on pullback rather than buying here

→ vs aggressive: PEG of 1.96 is pricing in growth not yet demonstrated; 48% implied growth vs actual 9.3% EPS growth in Q2 means either acceleration or multiple compression risk

→ vs aggressive: Higher-for-longer macro regime is hostile to multiple expansion; bull case requiring multiple expansion toward $839 is actively working against the setup

→ vs conservative: Downside scenario of 10-15% drawdown to $585-$595 requires BOTH Q3 miss AND multiple compression AND failure of structural setup; that's a tail scenario, not the central case

→ vs conservative: AI thesis dismissal as 'CEO PowerPoint' is lazy analysis; Marc Casper has compounded through multiple cycles since 2009, and 2028 organic growth target is a credible signal from credible operator

→ vs conservative: Precure JV has near-term narrative value that moves tape even without current-quarter revenue; dismissing it for not appearing in next print underrates how narrative drives short-term price action

→ vs conservative: '96% probability no rate cuts' is not new information—it's been the regime for months and market has already priced it; creating macro headwind from already-discounted reality is incorrect

→ vs conservative: 30-50% trim may be too aggressive given bullish technical setup and breakout continuation case at $680-$700; giving back that much position means giving up that much upside if breakout plays out